stockportfolio.pro
Stocks / QURE vs RAPP
QURE vs RAPP
uniQure N.V. and Rapport Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| uniQure N.V. (QURE) | Rapport Therapeutics, Inc. (RAPP) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $16.10M | $0 |
| Net income (latest FY) | $-198.97M | $-111.48M |
| Revenue growth (5y CAGR) | -15.6% | — |
| Net margin | -1236.0% | — |
| Return on equity | -100.0% | -23.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open QURE — free Open RAPP — freeFrequently asked questions
Which is bigger, QURE or RAPP?
uniQure N.V. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, QURE or RAPP?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.